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ORIGINAL ARTICLE
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping:
towards personalized medicine in atopic dermatitis
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C.A.F. Bruijnzeel-Koomena, D.J. Hijnena, R.H. Van Schaikc,d and M.S. De Bruin-Wellera
aDepartment of Dermatology and Allergology; bDepartment of Clinical Pharmacy; cDepartment of Clinical Chemistry and Hematology, University
Medical Center Utrecht, Utrecht, the Netherlands; dDepartment of Clinical Chemistry, Erasmus University Medical Center Rotterdam, Rotterdam,
the Netherlands
ABSTRACT
Atopic dermatitis (AD) is a very common chronic inflammatory skin disease requiring long-term treatment.
Mycophenolic acid (MPA) is used off-label in treatment of patients with severe AD failing Cyclosporin A
(CsA) treatment, however clinical efficacy is observed in only half of the AD patients. In blood, MPA levels
are known to have a large interindividual variability. Low MPA exposure and increased enzyme activity
correlates with the presence of UGT1A9 polymorphisms. In this retrospective study, 65 adult AD patients
treated with MPA were classified as responder or non-responder to MPA treatment. UGT1A9 polymor-
phisms were determined using PCR. A significantly higher number of UGT1A9 polymorphisms was found
in the group that did not respond to MPA treatment. Of the patients that carried a UGT1A9 polymorph-
ism, 85.7% were non-responsive to MPA treatment. This implies that non-responsiveness in AD patients is
more likely to occur in carriers of a UGT1A9 polymorphism. In a binary logistic regression analysis the
odds ratio (OR) was 8.65 (95% confidence interval: 0.93–80.17). Our results show that UGT1A9 polymor-
phisms can be used to identify patients with non-responsiveness to MPA. Patients with UGT1A9 polymor-
phisms might benefit from higher MPA dosage.
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Introduction
Atopic dermatitis (AD) is one of the most common chronic inflam-
matory skin diseases worldwide. The lifetime prevalence of AD is
estimated between 15–30% in children and 2–10% in adults (1,2).
AD is characterized by intense itching and follows a relapsing and
remitting course (3). The pathogenesis of AD is multifactorial and
involves genetic, immunologic and environmental factors (4). In
the management of AD, stabilization of the disease by prevention
of exacerbations is the major treatment goal; therefore long-term
treatment is often indicated.
Although the majority of the AD patients can be adequately
treated with topical treatment and/or UV-light therapy, there is
a large group of patients in whom oral immunosuppressive
drugs are indicated. Various immunosuppressive drugs are used
in AD, including Cyclosporin A (CsA), mycophenolic acid (MPA),
methotrexate, azathioprine and oral corticosteroids (5). In many
countries, CsA is the only registered oral immunosuppressive
drug for AD and therefore often first choice of treatment in
severe AD (5).
MPA is used off-label in patients with severe AD who have
failed CsA treatment (6). MPA inhibits the de novo purine synthesis
by arresting the cell cycle at the G0/G1 to the S transition phase
(7,8), which results in selective inhibition of cell proliferation of
B- and T cells (6). Since MPA does not influence the survival of
activated B and T cells, it has a delayed clinical response of
approximately two to three months (9). The efficacy of MPA in AD
has been proven in clinical studies (6,9). However, in clinical
practice, MPA is ineffective in nearly half of the AD patients
(10,11). To date, response to treatment with MPA has been very
difficult to predict. Delayed clinical response and the difficulties to
adequately predict MPA response may result in the fact that some
patients are treated with MPA for several months without any
clinical benefit.
In blood, MPA levels are known to have a large interindivid-
ual variability. This has been observed in kidney transplant
recipients, in whom a lower level of MPA exposure is closely
associated with lower efficacy of drug therapy and acute rejec-
tion of the transplanted organ (12,13). Low MPA exposure and
increased enzyme activity of the metabolizing enzyme uridine
diphosphate-glucuronosyltransferase 1A9 (UGT1A9) correlate to
the presence of single nucleotide polymorphisms (SNPs) in the
gene promotor region (275T>A and/or 2152C> T) (12,13). MPA
is predominantly metabolized by the enzyme UGT1A9 to mainly
the inactive phenolic-glucuronide metabolite. Therefore,
increased UGT1A9 activity due to SNPs would result in lower
MPA exposure in serum. We hypothesized that also for AD
patients, low MPA exposure due to the presence of UGT1A9
polymorphisms might contribute to the inefficacy during MPA
treatment. This would enable prediction of non-response based
on UGT1A9 polymorphisms in the future (Figure 1).
In this study, we evaluated the difference in frequency of
UGT1A9 polymorphisms between responders and non-responders
in AD patients treated with MPA, and found a positive association
between the presence of the polymorphisms and non-
responsiveness.
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Materials and methods
Study population
In a retrospective cohort study, 65 patients with severe AD treated
with MPA 1440mg/day at the University Medical Center Utrecht
between January 1st 2004 and January 31st 2016 were included.
Data were collected on March 15th 2016. Patients were diagnosed
with AD according to the criteria of Hanifin and Rajka (14).
The response to MPA treatment was assessed based on a 6-
point Investigators’ Global Assessment (IGA) (15). Patients were
classified as responders in case the IGA decreased at least two
points after a minimum of three months of treatment, and as
non-responder in case the decrease in IGA was less than two
points.
The study was approved by the Institutional Review Board of
the University Medical Center Utrecht, adhering to the Declaration
of Helsinki Principles.
Genotyping
The MagNA Pure LC system (Roche Diagnostics, Mannheim,
Germany) was used to isolate genomic DNA was isolated from
1ml EDTA serum. UGT1A9 genotyping was performed using
Taqman allelic discrimination assays on an ABI prism 7000
sequence detection system (Applied Biosystems, Nieuwerkerk a/d
IJssel, The Netherlands). For UGT1A9-275T>A polymorphism, PCR
was performed in a volume of 12.5 ll, containing assay-specific
primers, allele specific probes, TaqMan Universal PCR Master Mix,
and genomic DNA (12.5 ng). Genotypes were scored by measuring
allelic-specific fluorescence using SDS 1.2.3 software (Applied
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). For
UGT1A9–2152C> T polymorphism, genomic DNA (12.5 ng) was
amplified in a volume of 50 ll, PCR buffer II (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands), 1.75mmol/l MgCl2,
0.2mmol/l deoxynucleotide triphosphates (Roche Diagnostics,
Mannheim, Germany), 1.25U AmpliTaq Gold (PerkinElmer,
Waltham, MA, US), and 40 pmol of each primer. PCR products
were incubated with 10U TruI for two hours. Fragments were sep-
arated by electrophoresis on a 3% agarose gel with ethidium
bromide staining.
Statistical analysis
Statistical analysis was performed using SPSS (for Windows, ver-
sion 21.0, SPSS Inc., Chicago, IL, US). Pearson’s Chi square test or
Fisher exact test was used to compare categorical data between
groups (e.g. responder and non-responder to MPA treatment). The
strength of the association between UGT1A9–275/2152 geno-
type and response to MPA treatment was calculated using binary
logistic regression. Odds ratios (OR) were stated with 95% confi-
dence intervals (95% CI). Probability levels of 0.05 and below were
considered to indicate statistical significance.
Results
Out of 65 patients, 33 were classified as MPA responder and 32
were classified as MPA non-responder. Patient characteristics are
shown in Table 1. The UGT1A9–275T>A and UGT1A9–2152C> T
SNPs were found in seven patients as heterozygous, with all seven
heterozygous patients having both SNPs. This prevalence is similar
to those previously described in the Caucasian population (12).
The presence of UGT1A9 polymorphisms was significantly higher
in the patient group that did not respond to MPA treatment com-
pared to the group that did respond to MPA treatment (Table 1).
One out of seven (14.28%) UGT1A9 polymorphism carriers was a
responder, and six out of seven (85.71%) patients were non-res-
ponders to MPA treatment. This implies that non-responsiveness
in AD patients is more likely to occur in carriers of a UGT1A9 poly-
morphism. In a binary logistic regression analysis, adjusting
for age and gender, the OR was 8.65 (95% confidence
Figure 1. Pharmacogenomics in AD patients treated with MPA. Low MPA exposure and increased enzyme activity correlate to the presence of UGT1A9 polymorphisms.
It is likely that these UGT1A9 polymorphisms occur in AD patients treated with MPA. We hypothesized that low MPA exposure due to the presence of UGT1A9 poly-
morphisms might contribute to the inefficacy during MPA treatment. This would enable prediction of non-response based on UGT1A9 polymorphisms in the future.
Table 1. Baseline table of patient characteristics.
Total (n¼ 65) Responders (n¼ 33) Non-responders (n¼ 32) p values
Male, n (%) 40 (62.5) 23 (69.7) 17 (53.8) .226
Age in years (mean ±) 42.5 (14.0) 39.9 (14.4) 45.2 (13.1) .132
Duration of MPA treatment in days (mean ±) 534.94 (616.7) 763.1 (753.6) 292.0 (277.5) .063
UGT1A9 275T> A and 2152C> T heterozygote patients, n (%) 7 (10.7) 1 (3.0) 6 (18.8) .033
p< .05.
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interval: 0.93–80.17) (Table 2). Significance was not reached, prob-
ably due to the small number of patients.
Discussion
Pharmacogenomics are increasingly used in the in the manage-
ment of transplantation patients, however data in chronic inflam-
matory diseases, such as AD are scarce.
To the best of our knowledge, this is the first study to evaluate
the effect of UGT1A9 polymorphisms on MPA therapy responsive-
ness in AD. A significantly higher number of UGT1A9 polymor-
phisms was found in patients who did not respond to MPA
treatment compared to patients who did respond to MPA
treatment.
Since previous studies reported an association between the
presence of UGT1A9 polymorphisms and low MPA exposure, the
non-responsiveness to MPA in patients with UGT1A9 polymorph-
ism is presumably due to low MPA exposure (13). The therapeutic
strategy in non-responsive UGT1A9 polymorphism carriers would
have been to prescribe a higher dosage of MPA and thereby
increasing MPA exposure.
Our findings are consistent with previous studies investigating
UGT1A9 polymorphisms in renal transplant patients, showing a
statistically significantly higher rate of acute rejection of the graft
in UGT1A9 heterozygous renal transplant recipients (13,16).
Remarkably, one out of seven patients with UGT1A9 polymor-
phisms, did respond adequately to MPA treatment. A possible
explanation is that this patient has an extra genetic polymorphism
in UGT1A9, resulting in an overall decrease of UGT1A9 activity,
which would increase MPA exposure in contrary to expectations
based on the 275 SNP, as this is described before in other stud-
ies (17,18).
Treatment options in patients with severe AD are very limited
at this moment. CsA is often the drug of first choice in these
patients, however nearly half of the patients have to discontinue
treatment due to side effects and/or inefficacy (19). MPA is an
interesting second choice treatment option in severe AD patients,
as the side effect profile seems to be better than most other oral
immunosuppressive drugs used in AD (11,20). However, previous
studies have shown that around half of the AD patients do not
respond to MPA (10,11). Prediction of treatment response to MPA
in AD is very valuable, since treatment response can only be
determined after three to four months of treatment.
In conclusion, this study found an association between
UGT1A9 polymorphisms and non-responsiveness to MPA treat-
ment in severe AD patients. In the non-responder group, six out
of 32 patients carried a UGT1A9 polymorphism. This means that
pretreatment screening for UGT1A9 polymorphisms could have
identified 19% of the patients with non-responsiveness to MPA
treatment. Although this is a relatively small percentage, it does
show the potential benefits of pharmacogenetic screening for
UGT1A9 in AD. Future research is needed to identify other SNPs
and further optimize MPA treatment to ensure maximal efficacy
with minimal side effects. Although pharmacogenomics are
scarcely used in dermatological research, it enables “personalized
medicine” by prescribing drugs based on the genetic makeup of
an individual.
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